Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response

Immunology

Volumn 142, Issue 3, 2014, Pages 442-452

  Lasfar, Ahmed ^a,b   Cook, Jeffry R ^c   Cohen Solal, Karine A ^b,d   Reuhl, Kenneth ^a,b   Kotenko, Sergei V ^e   Langer, Jerome A ^c   Laskin, Debra L ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cell types; Constitutive interferon; Interferon receptor paradigm; Interferon response; T cells; Type I and type II interferon receptors

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; GAMMA INTERFERON RECEPTOR 2; INTERFERON; INTERFERON ALPHA RECEPTOR 1; INTERFERON ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL TYPE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE RESPONSE; EMBRYO; GENE DISRUPTION; HEMATOPOIETIC CELL; IN VITRO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REGULATORY MECHANISM; SPLEEN CELL;

CELL TYPES; CONSTITUTIVE INTERFERON; INTERFERON RECEPTOR PARADIGM; INTERFERON RESPONSE; T CELLS; TYPE I AND TYPE II INTERFERON RECEPTORS;

ANIMALS; INTERFERON TYPE I; INTERFERON-GAMMA; LIGANDS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 84902001438     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12273     Document Type: Article

References (60)

1. Diamond MS, Kinder M, Matsushita H et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003.
2. Dunn GP, Bruce AT, Sheehan KC et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005a; 6:722-9.
3. Dunn GP, Ikeda H, Bruce AT et al. Interferon-γ and cancer immunoediting. Immunol Res 2005b; 32:231-45.
4. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 2011; 1:476-86.
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70.
6. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007; 178:7540-9.
7. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011; 23:583-90.
8. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon λ: a new sword in cancer immunotherapy. Clin Dev Immunol 2011; 2011:349575.
9. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32.
10. Lefevre F, Guillomot M, D'Andrea S, Battegay S, La Bonnardiere C. Interferon-δ: the first member of a novel type I interferon family. Biochimie 1998; 80:779-88.
11. Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005; 106:299-346.
12. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19:2468-73.
13. Bromberg JF. Activation of STAT proteins and growth control. BioEssays 2001; 23:161-9.
14. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-64.
15. Kaur S, Uddin S, Platanias LC. The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res 2005; 25:780-7.
16. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5:375-86.
17. Takaoka A, Mitani Y, Suemori H, Sato M, Yokochi T, Noguchi S, Tanaka N, Taniguchi T. Cross talk between interferon-γ and -α/β signaling components in caveolar membrane domains. Science 2000; 288:2357-60.
18. Familletti PC, Rubinstein S, Pestka S. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol 1981; 78:387-94.
19. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Virol 1981; 37:755-8.
20. Lasfar A, Lewis-Antes A, Smirnov SV et al. Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66:4468-77.
21. Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uze G. Interferon-α and -β differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci USA 2005; 102:11917-22.
22. Piehler J, Thomas C, Garcia KC, Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 2012; 250:317-34.
23. Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uze G, Pellegrini S, Coccia EM. Differential responsiveness to IFN-α and IFN-β of human mature DC through modulation of IFNAR expression. J Leukoc Biol 2006; 79:1286-94.
24. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007; 282:20053-7.
25. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-21.
26. Erlandsson L, Blumenthal R, Eloranta ML, Engel H, Alm G, Weiss S, Leanderson T. Interferon-β is required for interferon-α production in mouse fibroblasts. Curr Biol 1998; 8:223-6.
27. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012; 36:166-74.
28. Gough DJ, Messina NL, Hii L et al. Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol 2010; 8:e1000361.
29. Rayamajhi M, Humann J, Kearney S, Hill KK, Lenz LL. Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections. Virulence 2010; 1:418-22.
30. Novelli F, Giovarelli M, Gentz R, Zucca M, di Pierro F, Garotta G, Forni G. Modulation of interferon-γ receptor during human T lymphocyte alloactivation. Eur J Immunol 1993; 23:1226-31.
31. Novelli F, Bernabei P, Ozmen L, Rigamonti L, Allione A, Pestka S, Garotta G, Forni G. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-γ is correlated with the differential expression of the α- and β-chains of its receptor. J Immunol 1996; 157:1935-43.
32. Bernabei P, Coccia EM, Rigamonti L et al. Interferon-γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 2001; 70:950-60.
33. Novelli F, D'Elios MM, Bernabei P, Ozmen L, Rigamonti L, Almerigogna F, Forni G Del Prete G. Expression and role in apoptosis of the α- and β-chains of the IFN-γ receptor on human Th1 and Th2 clones. J Immunol 1997; 159:206-13.
34. Rigamonti L, Ariotti S, Losana G et al. Surface expression of the IFN-γ R2 chain is regulated by intracellular trafficking in human T lymphocytes. J Immunol 2000; 164:201-7.
35. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6:34-55.
36. Giles FJ, Ozer H. α-Interferon in hematological malignancies. Curr Opin Biotechnol 1991; 2:847-50.
37. Gutterman JU. Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci USA 1994; 91:1198-205.
38. Kirkwood J. Cancer immunotherapy: the interferon-α experience. Semin Oncol 2002; 29:18-26.
39. Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE Jr, Stark GR, Kerr IM. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathways. EMBO J 1993; 12:4221-8.
40. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443-50.
41. Tanabe Y, Nishibori T, Su L, Arduini RM, Baker DP, David M. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-αβ responses in T lymphocytes. J Immunol 2005; 174:609-13.
42. Oh HM, Yu CR, Golestaneh N, Amadi-Obi A, Lee YS, Eseonu A, Mahdi RM, Egwuagu CE. STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem 2011; 286:30888-97.
43. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 2006; 281:14111-8.
44. Wang WB, Levy DE, Lee CK. STAT3 negatively regulates type I IFN-mediated antiviral response. J Immunol 2011; 187:2578-85.
45. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27:591-619.
46. Soh J, Donnelly RJ, Mariano TM, Cook JR, Schwartz B, Pestka S. Identification of a yeast artificial chromosome clone encoding an accessory factor for the human interferon γ receptor: evidence for multiple accessory factors. Proc Natl Acad Sci USA 1993; 90:8737-41.
47. Soh J, Donnelly RJ, Kotenko S et al. Identification and sequence of an accessory factor required for activation of the human interferon γ receptor. Cell 1994; 76:793-802.
48. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007; 366:525-39.
49. Piehler J, Roisman LC, Schreiber G. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem 2000; 275:40425-33.
50. Piehler J, Schreiber G. Mutational and structural analysis of the binding interface between type I interferons and their receptor IFNAR2. J Mol Biol 1999; 294:223-37.
51. Kotenko SV, Gallagher G, Baurin VV et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
52. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-8.
53. Krause CD, Pestka S. Historical developments in the research of interferon receptors. Cytokine Growth Factor Rev 2007; 18:473-82.
54. Pestka S. The interferon receptors. Semin Oncol 1997; 24:S9-18-S9-40.
55. Pestka S, Kotenko SV, Muthukumaran G, Izotova LS, Cook JR, Garotta G. The interferon γ (IFN-γ) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev 1997; 8:189-206.
56. Krause CD, Lavnikova N, Xie J, Mei E, Mirochnitchenko OV, Jia Y, Hochstrasser RM, Pestka S. Preassembly and ligand-induced restructuring of the chains of the IFN-γ receptor complex: the roles of Jak kinases, Stat1 and the receptor chains. Cell Res 2006; 16:55-69.
57. + T cell response. J Exp Med 1995; 181:961-71.
58. + effector cells default to the Th2 pathway in interferon-γ-deficient mice infected with Leishmania major. J Exp Med 1994; 179:1367-71.
59. Lu B, Ebensperger C, Dembic Z et al. Targeted disruption of the interferon-γ receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A 1998; 95:8233-8.
60. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K. γ Interferon (IFN-γ) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-γ ligand null-mutant mice. J Virol 1999; 73:5196-200.